脂微球载体前列腺素E1治疗戊型淤胆型肝炎疗效观察  

Effect of Lipid Microspheres Prostaglandin E1 in the Treatment of Viral Cholestatic Hepatitis E

作　　者：刘星[1] 王守兵[1] 张克祥[1] 孟召刚 

机构地区：[1]江苏省宿迁市泗阳县人民医院,江苏泗阳223700

出　　处：《中国医学创新》2012年第27期99-100,共2页Medical Innovation of China

摘　　要：目的:探讨脂微球载体前列腺素E1(前列地尔注射液)治疗戊型淤疸型肝炎的临床疗效和安全性。方法:73例患者分为治疗组(37例)和对照组(36例),治疗组用前列地尔注射液,对照组用苦黄注射液,其他保肝药物两组相同,疗程4周。结果:治疗组有效率86.49%(32/37),对照组有效率63.89%(23/36),两组比较差异有统计学意义(字2=5.02,P<0.05);治疗组治疗后TBil比对照组低,比较差异有统计学意义(t=2.17,P<0.05);ALT比较差异无统计学意义(P>0.05)。结论:前列地尔注射液联合其他保肝药物治疗戊型淤胆型肝炎退黄效果好,无明显不良反应。Objective：To observe the clinical efficacy and safety of lipid microspheres prostaglandin E1 for treatment of viral cholestatichepatitis E.Method：73 patients with viral cholestatic hepatitis E were randomly divided into treatment group（n=37）and control group（n=36）.Two groups took the same liver protecting drugs for 4 weeks and lipid microspheres prostaglandin E1 for treatment group, Kuhuang injection for control group.Result：The efficacy rate was 86.49% in treatment group, while that is 63.89% in control group, they were significantly difference between two groups（P〈0.OS）.TBil was lower in treatment group than that in control group（P〈0.05）after treatment. Conclusion：Lipid microspheres prostaglandin E1 is an effective and safe drug for treatment of viral cholestatic hepatitis E.

关 键 词：脂微球载体前列腺素E1 戊型肝炎 淤胆型肝炎 

分 类 号：R512.6[医药卫生—内科学]